Sign in
Taking peoplePhase 1/2

DON in Pediatric Cerebral Malaria

Key facts

Who runs it
Douglas Postels, MD, MS
Where
Malawi2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
152 people, planned
Started
16 Aug 2022
Expected to end
30 Nov 2028
Type of study
Interventional, 13 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • 6-diazo-5-oxo-L-norleucine (DON)
  • Placebo
Record updated
23 October 2026

Who can take part

Age
12 months to 14 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 41 criteriaShow less

Who can take part

  • For Healthy Adults (Part 1):
  • 18 years and older
  • Informed consent obtained and ICF signed
  • Temperature ≤ 37.5 °C
  • BMI 18.5-25 kg/m2
  • Creatinine ≤ 110 mmol/L (≤ 1.2 mg/dL; males) or ≤ 90 mmol/L (≤ 1.0 mg/dL; females)
  • Hemoglobin ≥ 7 g/dL or hematocrit/ packed-cell volume (PCV) ≥ 20%
  • Thick or thin blood smear negative for asexual forms of P. falciparum
  • Negative pregnancy test for persons of child-bearing potential; For Adults with Uncomplicated Malaria (Part 1):
  • 18 years and older
  • Informed consent obtained and ICF signed
  • Temperature ≥ 38 °C or history of fever in the past 24 hours
  • Thick or thin blood smear positive for asexual forms of P. falciparum (parasite count and speciation documented)
  • Hemoglobin ≥ 7 g/dL or hematocrit/ PCV ≥ 20%
  • BMI 18.5-25 kg/m2
  • Creatinine ≤ 110 mmol/L (≤ 1.2 mg/dL; males) or ≤ 90 mmol/L (≤ 1.0 mg/dL; females)
  • Glasgow coma score of 15
  • Respiratory rate ≤ 20 breaths/ minute
  • Oxygen saturation ≥ 90% on room air
  • Negative pregnancy test for person of child-bearing potential; For Children with Cerebral Malaria (Part 2):
  • Age 12 months-14 years old
  • Informed consent obtained and ICF signed by parent or guardian
  • Temperature ≥ 38 °C or history of fever in the last 24 hours
  • Thick or thin blood smear positive for asexual forms of P. falciparum
  • Blantyre coma score ≤ 2
  • No other explanation for coma by history or physical exam
  • Hematocrit or PCV ≥ 18%
  • Negative pregnancy test for persons of child-bearing potential
  • Creatinine ≤ 1.5 mg/dL
  • Aspartate aminotransferase (AST) < 280 IU/L
  • Alanine aminotransferase (ALT) < 195 IU/L

Who cannot take part

  • Pregnancy or lactation (participants of child-bearing potential ages 9-59 years will undergo pregnancy testing prior to administration of the intervention)
  • Currently taking highly active antiretroviral therapy (HAART)
  • Currently taking anti-tuberculosis medications
  • Have taken a CYP3A4 inhibitor within 7 days of enrollment
  • Allergy to ondansetron or ceftriaxone; Additional Exclusion Criteria for Children with Cerebral Malaria (Part 2):
  • Cloudy cerebrospinal fluid (indicative of a probable bacterial central nervous system infection)
  • Allergy to ondansetron or ceftriaxone
  • Participants attempting to become pregnant
  • Severe malnutrition (>3 standard deviations below the mean weight for height and/ or mid-upper arm circumference (MUAC) ≤11.5 cm
  • Coma for > 72 hours

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the safety of a single intravenous dose of DON in healthy adults, adults with uncomplicated malaria, and children 12 months-14 years old with clinically defined Cerebral Malaria. The main objectives are:

Read full original descriptionShow less

* Evaluate the safety of a single intravenous dose of DON in healthy adults and adults with uncomplicated malaria ( Part 1) * Determine the safety of a single dose of DON in children 12 months-14 years old with World Health Organization (WHO) clinically defined CM (Part 2 :Cohort 1-4) * Determine the pharmacokinetic (PK) profile of a single dose of DON in healthy adults, adults with uncomplicated malaria and children with CM (Part 1, and Cohorts 1-4 of Part 2) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with CM is associated with improved intracerebral blood flow dynamics on transcranial doppler (TCD) (Part 2 :Cohort 1-4) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with CM is associated with a reduction in brain volume score on magnetic resonance imaging (MRI) (Part 2 :Cohort 1-4) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with cerebral malaria is associated with changes in electroencephalogram (EEG) pattern (Part 2 :Cohort 1-4) * Exploratory: Explore the metabolic mechanisms of action of adjunctive DON in children with CM

Healthy adult participants will receive:

* anti-emetic ondansetron * one dose of DON

Adults with uncomplicated malaria will receive:

* anti-emetic ondansetron * one dose of DON * artemisinin-combination therapies per Malawi Ministry of Health guidelines

Pediatric participants will receive:

* one dose of DON * anti-emetic ondansetron and per Malawi Ministry of Health guidelines: * enteral lumefantrine-artemether therapy, and * artesunate therapy

The 13 groups in the trial

  • Dose escalation in healthy Malawian adults - 0.1 mg/kg IV DONTreatment being tested

    The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in healthy Malawian adults - 1.0 mg/kg IV DONTreatment being tested

    The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in healthy Malawian adults - 5.0 mg/kg IV DONTreatment being tested

    The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in healthy Malawian adults - 10.0 mg/kg IV DONTreatment being tested

    The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian adults with uncomplicated malaria - 0.1 mg/kg IV DONTreatment being tested

    The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian adults with uncomplicated malaria - 1.0 mg/kg IV DONTreatment being tested

    The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian adults with uncomplicated malaria - 5.0 mg/kg IV DONTreatment being tested

    The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian adults with uncomplicated malaria - 10.0 mg/kg IV DONTreatment being tested

    The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 1Treatment being tested

    After adult doses are shown to be safe. Of the first 6 children with cerebral malaria enrolled, 4 will receive 0.1 mg/kg IV DON, and 2 will receive placebo.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 2Treatment being tested

    10 participants will receive 0.1 mg/kg IV DON, and 2 will receive placebo.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian children with cerebral malaria - 1.0 mg/kg IV DON - Cohort 3Treatment being tested

    14 participants will receive 1.0 mg/kg IV DON, and 4 will receive placebo.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian children with cerebral malaria - 0.1 or 1.0 mg/kg IV DON - Cohort 4Treatment being tested

    36 participants will receive 0.1 mg/kg IV DON (n=12) or 1.0 mg/kg IV DON (n=12), and 12 will receive placebo.

    Treatment: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian children with cerebral malaria - placeboPlacebo, for comparison

    Cohort 1 will dose 2 participants to receive placebo Cohort 2 will dose 2 participants to receive placebo Cohort 3 will dose 4 participants to receive placebo Cohort 4 will dose 12 participants to receive placebo

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
DON in Pediatric Cerebral Malaria: A Phase I/IIa Dose-Escalation Safety Study
Publications
Record updated
23 October 2026